Nasdaq Issues Delisting Warning to Jasper Therapeutics Over Sub-$1.00 Stock Price
Summary
Jasper Therapeutics received a formal notice from Nasdaq for failing to maintain the minimum $1.00 bid price for 30 consecutive business days. This follows multiple "going concern" warnings in recent financial reports and a recent announcement that the company is exploring strategic alternatives, including a potential sale. The company has 180 days, until November 30, 2026, to regain compliance and may consider a reverse stock split. This adds significant pressure and uncertainty to the company's already precarious financial situation.
At the time of this announcement, JSPR was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $0.42 to $7.19. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.